Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12614000744651
Ethics application status
Approved
Date submitted
3/06/2014
Date registered
14/07/2014
Date last updated
14/07/2014
Type of registration
Retrospectively registered

Titles & IDs
Public title
A comparison of the effects of different albumin solutions on severely ill adults in the intensive care unit.
Scientific title
Physiological and Biochemical Responses to Fluid Bolus Therapy with 4% versus 20% Human Albumin Solution in Critically Ill Adults
Secondary ID [1] 284726 0
Nil
Universal Trial Number (UTN)
Nil
Trial acronym
Nil
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Critical illness 292075 0
Condition category
Condition code
Other 292414 292414 0 0
Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)

Intervention/exposure
Study type
Observational
Patient registry
False
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Intravenous fluid bolus therapy with either 4% or 20% human albumin solution administered according to clinician preference
Intervention code [1] 289509 0
Not applicable
Comparator / control treatment
Direct comparison of physiological and biochemical parameters following admisnitrations of 4% versus 20% human albumin solutions
Control group
Dose comparison

Outcomes
Primary outcome [1] 292612 0
Mean arterial pressure
Timepoint [1] 292612 0
1, 2 and 4 hours post fluid bolus therapy
Secondary outcome [1] 308615 0
Hospital mortality
Timepoint [1] 308615 0
hospital discharge
Secondary outcome [2] 309330 0
Heart rate
Timepoint [2] 309330 0
1, 2 and 4 hours post fluid bolus therapy
Secondary outcome [3] 309331 0
Systolic blood pressure
Timepoint [3] 309331 0
1, 2 and 4 hours post fluid bolus therapy
Secondary outcome [4] 309332 0
Diastolic blood pressure
Timepoint [4] 309332 0
1, 2 and 4 hours post fluid bolus therapy
Secondary outcome [5] 309333 0
Serum sodium
Timepoint [5] 309333 0
1, 2 and 4 hours post fluid bolus therapy
Secondary outcome [6] 309334 0
serum chloride
Timepoint [6] 309334 0
1, 2 and 4 hours post fluid bolus therapy
Secondary outcome [7] 309335 0
serum base excess
Timepoint [7] 309335 0
1, 2 and 4 hours post fluid bolus therapy
Secondary outcome [8] 309336 0
serum creatinine
Timepoint [8] 309336 0
1, 2 and 4 hours post fluid bolus therapy

Eligibility
Key inclusion criteria
All adult ICU admissions who received either 4% or 20% (but not both) human albumin solution as fluid bolus therapy at our institution between April 2012 and March 2013
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Patients received both 4% and 20% solution within 24 hours of baseline

2. Patients who had previously received any human albumin solution during their ICU stay

Study design
Purpose
Duration
Selection
Timing
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/04/2012
Actual
1/11/2012
Date of last participant enrolment
Anticipated
26/02/2013
Actual
26/02/2013
Date of last data collection
Anticipated
Actual
Sample size
Target
200
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 2540 0
Austin Health - Austin Hospital - Heidelberg
Recruitment postcode(s) [1] 8222 0
3084 - Heidelberg

Funding & Sponsors
Funding source category [1] 289343 0
Self funded/Unfunded
Name [1] 289343 0
Country [1] 289343 0
Primary sponsor type
Individual
Name
Prof Rinaldo Bellomo
Address
Dept of Intensive Care,
Austin Health,
145 Studley road,
Heidelberg,
VIC 3084
Country
Australia
Secondary sponsor category [1] 288028 0
None
Name [1] 288028 0
Address [1] 288028 0
Country [1] 288028 0
Other collaborator category [1] 277987 0
Individual
Name [1] 277987 0
Dr Jonathan Bannard-Smith
Address [1] 277987 0
Dept of Intensive Care,
Austin Health,
145 Studley Road,
Heidelberg,
VIc 3084
Country [1] 277987 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 291113 0
Local Ethics Committee
Ethics committee address [1] 291113 0
Ethics committee country [1] 291113 0
Australia
Date submitted for ethics approval [1] 291113 0
Approval date [1] 291113 0
28/06/2014
Ethics approval number [1] 291113 0
LNR/14/Austin/313

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 48914 0
Prof Rinaldo Bellomo
Address 48914 0
Dept of Intensive Care,
Austin Health,
145 Studley Road,
Heidelberg,
VIC 3084
Country 48914 0
Australia
Phone 48914 0
+61 (0)3 9496 5000
Fax 48914 0
Email 48914 0
[email protected]
Contact person for public queries
Name 48915 0
Rinaldo Bellomo
Address 48915 0
Dept of Intensive Care,
Austin Health,
145 Studley Road,
Heidelberg,
VIC 3084
Country 48915 0
Australia
Phone 48915 0
+61 (0)3 9496 5000
Fax 48915 0
Email 48915 0
[email protected]
Contact person for scientific queries
Name 48916 0
Rinaldo Bellomo
Address 48916 0
Dept of Intensive Care,
Austin Health,
145 Studley Road,
Heidelberg,
VIC 3084
Country 48916 0
Australia
Phone 48916 0
+61 (0)3 9496 5000
Fax 48916 0
Email 48916 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.